Geron Corporation (NASDAQ:GERN – Get Free Report) EVP Timothy Williams bought 12,000 shares of the firm’s stock in a transaction on Monday, November 16th. The stock was acquired at an average cost of $0.94 per share, for a total transaction of $11,280.00. Following the completion of the purchase, the executive vice president directly owned 12,000 shares in the company, valued at approximately $11,280. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Geron Trading Down 2.6%
Shares of GERN traded down $0.03 during trading on Monday, reaching $0.94. 9,306,519 shares of the company traded hands, compared to its average volume of 14,085,533. The stock has a 50-day simple moving average of $1.18 and a 200-day simple moving average of $1.40. The company has a quick ratio of 4.61, a current ratio of 6.31 and a debt-to-equity ratio of 0.53. Geron Corporation has a twelve month low of $0.84 and a twelve month high of $2.01. The stock has a market cap of $606.81 million, a PE ratio of -11.77 and a beta of 0.62.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in GERN. Nantahala Capital Management LLC bought a new stake in shares of Geron in the 2nd quarter worth approximately $15,648,000. Bank of America Corp DE acquired a new position in Geron during the second quarter worth about $4,524,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Geron in the 2nd quarter worth approximately $2,982,000. Janus Henderson Group PLC grew its holdings in shares of Geron by 826.7% in the 1st quarter. Janus Henderson Group PLC now owns 2,218,196 shares of the biopharmaceutical company’s stock worth $3,304,000 after acquiring an additional 1,978,839 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Geron by 144.1% in the first quarter. Renaissance Technologies LLC now owns 1,799,521 shares of the biopharmaceutical company’s stock worth $2,681,000 after buying an additional 1,062,355 shares during the period. Hedge funds and other institutional investors own 73.71% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have commented on GERN. Needham & Company LLC lowered their price target on shares of Geron from $4.00 to $2.50 and set a “buy” rating for the company in a report on Wednesday, October 28th. Wedbush lowered their price objective on Geron to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, October 28th. Finally, Weiss Ratings upgraded Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 9th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.75.
View Our Latest Research Report on GERN
Geron Company Profile
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
Featured Articles
- Five stocks we like better than Geron
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
